ACCESS RESTRICTED TO VERIFIED HEALTH PROFESSIONALS 

For healthcare professionals

The science behind Nurochek-Pro

An objective, interpretive EEG assessment aid for the diagnosis of mild traumatic brain injury — developed, verified and validated to perform as intended.

Steady-state visual evoked potential Prescription use only ISO 13485:2016 certified

How it works

An objective neurological signal, read against an established reference.

Nurochek-Pro measures the brain's steady-state response to visual stimulation — a signal that does not depend on patient self-report — and interprets it as an adjunct to standard neurological assessment.

1

Measure

A non-invasive recording captures the steady-state visual evoked potential (SSVEP) response.

2

Compare

The reading is compared against a reference database within a validated classification model.

3

Interpret

The result supports clinical judgement when used alongside a standard neurological assessment.

Clinical validation

Clinical performance.

Clinical evaluation concluded that the device performs as intended for its labelled purpose. Nurochek-Pro demonstrated the following performance when used as an adjunct to standard neurological assessment.

87.37%

Sensitivity

95% CI 78.97–93.30

64.56%

Specificity

95% CI 56.56–71.99

75.96%

Balanced accuracy

Sensitivity & specificity, averaged

Reported figures

Nurochek-Pro classifier performance.

Point estimates with 95% confidence intervals from clinical evaluation.

Nurochek-Pro classifier performance.
Sensitivity [95% CI] Specificity [95% CI] Balanced accuracy
87.37%95% CI 78.97–93.30 64.56%95% CI 56.56–71.99 75.96%

Study population

Who the model was evaluated on.

Participant demographics from clinical evaluation of the Headsafe mTBI classification model. Two research groups were included: post-episode injured non-concussed participants (PE) and clinically concussed participants (CNXO).

12–44

Age range (years)

Labelled indication band

≈20yr

Median age

Comparable across groups

Predictive value

Predictive value varies with prevalence.

Positive and negative predictive value depend on how common mTBI is in the population assessed. At a reference prevalence of about 38%, Nurochek-Pro showed the values below.

89.4% Negative predictive value
Confidence in a negative result at ~38% prevalence.
59.5% Positive predictive value
Confidence in a positive result at ~38% prevalence.

Predictive value of Nurochek-Pro vs prevalence of mTBI

NPV PPV Reference prevalence (~38%)

Quality & regulatory

Developed under a certified quality system.

The Nurochek-Pro System has undergone design verification and validation under Headsafe's quality management system.

ISO 13485:2016

Quality management system certified by Intertek for medical devices.

MDSAP-covered

Within the scope of a Medical Device Single Audit Programme quality system.

Prescription use only

Indicated as an adjunct to a standard neurological assessment by a clinician.